Angiogenic Factors in the Conservative Management of Gestational Hypertension

Gestational Hypertension Clinical Trial

Official title: Use of Angiogenic Factors in the Conservative Management of Gestational Hypertension. Prospective, Randomised, Controlled Study.

Status Not yet recruiting

Clinical Trial Summary

Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit. One of the most controversial scenarios is gestational hypertension, a group of hypertensive disorders considered the mildest form of the pre-eclamptic spectrum, where current recommendations indicate termination of pregnancy at 37 weeks. However, the decision is based on outdated guidelines developed at a time when angiogenic factors were just beginning to be known. The purpose of the study is to use angiogenic factors as a guide to decide the most appropriate gestational age for termination of pregnancy in patients diagnosed with gestational hypertension.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Gestational Hypertension
• Hypertension
• Hypertension, Pregnancy-Induced

• NCT number: NCT06123377
• Study type: Interventional
• Source: Saint Thomas Hospital, Panama
• Contact: Osvaldo Reyes, MD
• Phone: +507 65655041
• Email: oreyespanama@yahoo.es
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2024
• Completion date: September 30, 2024